Clinical Cancer Research
The Journal of Clinical and Translational Research
November 15, 2010 • Volume 16 • Number 22

Contents

Highlights of This Issue 5369

SPECIAL FEATURES

5371 Highly Active Antitumor Therapy (HAATT) for Epidermal Growth Factor Receptor-Mutant Lung Cancer
Juliann Chmielecki and William Pao
See article p. 5489

5374 Target of Rapamycin Signaling in Leukemia and Lymphoma
Collin Vu and David A. Fruman

5381 Phase III Clinical Trial Development: A Process of Chutes and Ladders
David M. Dilts, Steven K. Cheng, Joshua S. Crites, Alan B. Sandler, and James H. Doroshow
See article p. 5557

HUMAN CANCER BIOLOGY

5390 Hypoexpression and Epigenetic Regulation of Candidate Tumor Suppressor Gene CADM-2 in Human Prostate Cancer
Guimin Chang, Shuping Xu, Rajiv Dhir, Uma Chandran, Denise S. O’Keefe, Norman M. Greenberg, and Jeffrey R. Gingrich

5402 MSH6 and MUTYH Deficiency Is a Frequent Event in Early-Onset Colorectal Cancer
Maria Dolores Giraldez, Francesc Balaguer, Luis Bujanda, Miriam Cuatrecasas, Jenifer Muñoz, Virginia Alonso-Espinaco, Mikel Larrizabal, Anna Petit, Victoria Gonzalo, Teresa Ocaña, Leticia Moreira, José María Enriquez-Navascués, C. Richard Boland, Ajay Goel, Antoni Castells, and Sergi Castellví-Bel

5414 Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect

5424 Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Nicolas Chapuis, Jerome Tamburini, Alexia S. Green, Christine Vignon, Valerie Bardet, Aymeric Neyret, Melanie Pannetier, Lise Willems, Sophie Park, Alexandre Macone, Sauveur-Michel Maira, Norbert Ifrah, François Dreyfus, Olivier Herault, Catherine Lacombe, Patrick Mayeux, and Didier Bouscary

5436 The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
Sara A. Flanigan, Todd M. Pitts, S. Gail Eckhardt, John J. Tentler, Aik Choon Tan, Andrew Thorburn, and Stephen Leong

5447 Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity
Robert J. Kinders, Melinda Hollingshead, Scott Lawrence, Jiuping Ji, Brian Tabb, William M. Bonner, Yves Pommier, Larry Rubinstein, Yvonne A. Evrard, Ralph E. Parchment, Joseph Tomaszewski, and James H. Doroshow; for the National Cancer Institute Phase 0 Clinical Trials Team
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5458</td>
<td>Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses</td>
<td>Weiyi Peng, Yang Ye, Brian A. Rabinovich, Chengwen Liu, Yanyan Lou, Minying Zhang, Mayra Whittington, Yan Yang, Willem W. Overwijk, Gregory Lizée, and Patrick Hvu</td>
<td>5511</td>
</tr>
<tr>
<td>5469</td>
<td>Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models</td>
<td>Ansarg Santel, Manuela Aleku, Nadine Röder, Kristin Möpert, Birgit Durieux, Oliver Janke, Oliver Keil, Jens Endruschat, Sibylle Dames, Christian Lange, Mona Eisermann, Kathrin Löfler, Melanie Fechner, Gerald Fisch, Christiane Vank, Ute Schaeper, Klaus Giese, and Jörg Kaufmann</td>
<td>5522</td>
</tr>
<tr>
<td>5489</td>
<td>Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer</td>
<td>Kenichi Suda, Isao Murakami, Tatsuya Katayama, Kenji Tomizawa, Hirotaka Osada, Yoshitaka Sekido, Yoshihiko Maehara, Yasushi Yatabe, and Tetsuya Mitsudomi</td>
<td>5539</td>
</tr>
<tr>
<td>5499</td>
<td>Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia</td>
<td>Chengzhi Xie, Holly Edwards, Xuelian Xu, Hui Zhou, Steven A. Buck, Mark L. Stout, Qun Yu, Jeffrey E. Rubnitz, Larry H. Matherly, Jeffrey W. Taub, and Yubin Ge</td>
<td>5539</td>
</tr>
<tr>
<td>5499</td>
<td>Overexpression of High-Mobility Group Box 2 Is Associated with Tumor Aggressiveness and Prognosis of Hepatocellular Carcinoma</td>
<td>Jung-Hee Kwon, Jongmin Kim, Jin Young Park, Sun Mi Hong, Chang Wook Park, Seok Joo Hong, Sun Young Park, Yoon Jung Choi, In-Gu Do, Jae-Won Joh, Dae Shick Kim, and Kwan Yong Choi</td>
<td>5548</td>
</tr>
<tr>
<td>5481</td>
<td>Prognostic Significance of RNA-Dependent Protein Kinase on Non–Small Cell Lung Cancer Patients</td>
<td>Abujiang Pataer, Maria Gabriela Raso, Arlene M. Correa, Carmen Behrens, Koji Tsuta, Luisa Solis, Bingliang Fang, Jack A. Roth, Ignacio I. Wistuba, and Stephen G. Swisher</td>
<td>5548</td>
</tr>
<tr>
<td>5489</td>
<td>Expression, Cellular Distribution, and Prognostic Relevance of TRAIL Receptors in Hepatocellular Carcinoma</td>
<td>Lydia Kriegl, Andreas Jung, Jutta Engel, Rene Jackstadt, Alexander L. Gerbes, Eike Gallmeier, Jana A. Reiche, Heiko Hermeking, Antonia Rizzani, Christiane J. Bruns, Frank T. Kolligs, Thomas Kirchner, Burkhardt Göke, and Enrico N. De Toni</td>
<td>5549</td>
</tr>
<tr>
<td>5499</td>
<td>Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase II Study</td>
<td>Robert J. Amato, Robert E. Hawkins, Howard L. Kaufman, John A. Thompson, Piotr Tomczak, Cezary Szczylik, Mike McDonald, Sarah Eastty, William H. Shingler, Jackie de Belin, Madusha Goonewardena, Stuart Naylor, and Richard Harrop</td>
<td>5549</td>
</tr>
<tr>
<td>5499</td>
<td>Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer</td>
<td>Kenichi Suda, Isao Murakami, Tatsuya Katayama, Kenji Tomizawa, Hirotaka Osada, Yoshitaka Sekido, Yoshihiko Maehara, Yasushi Yatabe, and Tetsuya Mitsudomi</td>
<td>5549</td>
</tr>
<tr>
<td>5499</td>
<td>Mechanisms of Synergistic Antileukemic Interactions between Valproic Acid and Cytarabine in Pediatric Acute Myeloid Leukemia</td>
<td>Chengzhi Xie, Holly Edwards, Xuelian Xu, Hui Zhou, Steven A. Buck, Mark L. Stout, Qun Yu, Jeffrey E. Rubnitz, Larry H. Matherly, Jeffrey W. Taub, and Yubin Ge</td>
<td>5549</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5499</td>
<td>Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase II Study</td>
<td>Robert J. Amato, Robert E. Hawkins, Howard L. Kaufman, John A. Thompson, Piotr Tomczak, Cezary Szczylik, Mike McDonald, Sarah Eastty, William H. Shingler, Jackie de Belin, Madusha Goonewardena, Stuart Naylor, and Richard Harrop</td>
<td>5549</td>
</tr>
</tbody>
</table>
A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies

Steven K. Cheng, Mary S. Dietrich, and David M. Dilts

See commentary p. 5381

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

Charles Comins, James Spicer, Andrew Protheroe, Victoria Roulstone, Katie Twigger, Christine M. White, Richard Vile, Alan Melcher, Matt C. Coffey, Karl L. Mettinger, Gerard Nuovo, David E. Cohn, Mitch Phelps, Kevin J. Harrington, and Hardev S. Pandha

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks


Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

D. Ross Camidge, Scott A. Kono, Antonella Flacco, Aik-Choon Tan, Robert C. Doebele, Qing Zhou, Lucio Crino, Wilbur A. Franklin, and Mariela Varella-Garcia

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Thomas Winder, Wu Zhang, Dongyun Yang, Yan Ning, Pierre Bohanes, Armin Gerger, Peter M. Wilson, Alexandra Pohl, David J. Mauro, Christiane Langer, Eric K. Rowinsky, and Heinz-Josef Lenz

ABOUT THE COVER

Atu027, a liposomal siRNA, is a novel RNAi therapeutic for cancer therapy suppressing PKN3 gene expression in endothelial cells of the vasculature. In cultured human endothelial cells (HUVEC), Atu027 mediated downregulation of PKN3 led to increased levels of the adhesion protein vascular endothelial (VE)-cadherin. The different levels of VE-cadherin protein are depicted in this image in a color-coded manner reflecting highest VE-cadherin levels as red colored membrane staining. The authors show that Atu027 treatment modulates the vascular endothelium in a way that metastasis through the blood vessels to the lung is effectively inhibited. For further details, please see Santel and colleagues on page 5469 in this issue.
Clinical Cancer Research

16 (22)

Clin Cancer Res 2010;16:5369-5602.

Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/22

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/16/22. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.